CANCER

ALA’s cell targeting cancer treatment works in mice - human trials on track with manufacturing scale now achieved

Next Investors Jun 07, 2024

Our biotech Investment, Arovella Therapeutics (ASX: ALA) is developing an iNKT cell therapy platform to fight cancer, and is setting the stage for a Phase 1 clinical trial. Basically ALA’s treatment can find, identify and kill specific cancer cells, leaving other healthy cells unharmed,

ALA now funded to enter Phase 1 trial to test new cancer treatment tech on humans…

Next Investors Mar 26, 2024

Our Investment ALA is trialling a technology to find, target and attack ONLY cancer cells, leaving the rest of the body healthy and unimpacted.

New Deal: ALA can now target lung cancer, pancreatic cancer, gastric cancer

Next Investors Oct 12, 2023

Our preclinical biotech Investment, Arovella Therapeutics (ASX: ALA) has just announced that its cancer fighting cell-therapy may now also be able to more effectively target pancreatic, gastric and lung cancer.

ALA shows it can scale: Pathway towards an “off the shelf” cancer treatment

Next Investors Apr 17, 2023

This morning Arovella Therapeutics (ASX: ALA) released new data indicating its treatment, ALA-101, has the potential to be a novel, ‘off the shelf’ cell therapy to treat leukemias and lymphomas.

$1.5M annual cost savings allows ALA to focus on what really matters

Next Investors Oct 28, 2022

Arovella Therapeutics (ASX:ALA) announced on Wednesday that it had decided to phase out its legacy operations to fully focus on its CAR iNKT treatment for cancer.

$23M capped ALA partners with $1.1BN Imugene - Now Targeting 90% of Cancers

Next Investors Sep 27, 2022

Yesterday, Arovella Therapeutics (ASX:ALA) announced that it had signed a partnership agreement with $1.1BN capped Imugene to develop its technology to target solid tumour cancer cells.

Pre-result build up? The “big catalyst” in 2023

Finfeed Sep 02, 2022

Our biotech Investment and 2021 Biotech Pick of the Year, Dimerix (ASX:DXB), has been busy this year working towards its all important Phase 3 trial and first interim results. After our initial entry at 20c in August 2021, our Investment in DXB is currently sitting below that price at 14.5 cents.

PharmAust's phase II monepantel trials a success

Finfeed Archived May 12, 2020

PharmAust (ASX: PAA) has released promising data in relation to its monepantel canine trial, investigating the anti-cancer effects of monepantel tablets in dogs.

OncoSil on verge of CE Mark approval

Finfeed Archived Feb 27, 2020

The coming 12 months is shaping up as a watershed stage in the history of Oncosil Medical Ltd (ASX:OSL) as it flags the finalisation of commercialisation plans for its OncoSil™ device ahead of CE marking early in 2020.